Case 2: A 68-year-old female with a KRAS-mutant left-sided colon adenocarcinoma, comorbidities, and previous chemotherapy tolerability issues; never exposed to FTD/TPI. This evidence concerns the gene KRAS and colon adenocarcinoma.